Beta Drugs Limited has informed the Exchange about General Updates
BETA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Beta Drugs Limited has filed a clarification with the NSE in response to exchange observations regarding a Corrigendum to the Notice of an Extra Ordinary General Meeting. The filing includes the company's shareholding pattern before and after a proposed preferential issue of equity shares, factoring in outstanding CCDs (Compulsorily Convertible Debentures). The pre-issue share capital stands at 1,01,36,890 shares, which expands to 1,10,85,872 shares post-issue — an addition of approximately 9,48,982 equity shares. Promoter holding dilutes from 64.63% to 59.10% due to the new issuance, while institutional investor holding nearly triples from 3.43% to 9.14%, indicating a significant institutional placement in the preferential issue.
The dilution of promoter holding by over 5 percentage points and the tripling of institutional investor stake suggest a notable change in the company's ownership structure, which could be positive if it reflects institutional confidence but may weigh on promoter-level control.